Ambrosia Biosciences landed $100 million in oversubscribed Series B financing to advance an oral small-molecule GLP-1 program it says is designed to compete with Novo Nordisk’s Wegovy. The company will use the funding to push its oral GLP-1 candidate toward clinical development, alongside other cardiometabolic pipeline programs targeting pathways such as GIP and amylin. The round was co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital, marking a major capital infusion for a company formed by former Array BioPharma scientists after Pfizer acquired the oncology firm. Ambrosia’s strategy reflects investor focus on differentiated oral incretin profiles—especially as oral options begin to compete more directly with injections. With additional oral obesity assets already in the clinic, Ambrosia is betting that combinability and convenience can support meaningful differentiation in a market approaching $100 billion-plus in annual sales estimates by the end of the decade.